glp-1 agonists cardiovascular diseases and mortality outcomes with receptor vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Mechanisms by which GLP-1 agonists
Description
Wei H, Bu R, Yang Q, Jia J, Li T, Wang Q, Chen Y
Meta-analyses have confirmed the benefit of GLP-1 RAs as a class in both secondary and primary prevention of cardiovascular disease, and in reduction of adverse kidney outcomes in people with T2D (Kristiensen et al, 2019
He W, Li J
The first factor identified was gastric inhibitory polypeptide (GIP), which was thought to increase glucose-stimulated insulin secretion
Sato, Y
To view a copy of this license, visit About this article Cite this article Pinto, L.C., Falcetta, M.R., Rados, D.V
